locally advanced NSCLC - maintenance (M) | metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |||
laNSCLC - M - all population | mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - EGFR mutant | mNSCLC - L2 - PDL1 positive | |
durvalumab based treatment | |||||
durvalumab alone | PACIFIC | MYSTIC ... | MYSTIC ... | ARCTIC ... | |
durvalumab plus osimertinib | CAURAL ... |